Testing stored control-arm specimens could dramatically increase statistical power yet reduce costs in cancer screening trials.
作者信息
Katki Hormuzd A
机构信息
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, United States.
出版信息
J Natl Cancer Inst. 2025 Mar 1;117(3):393-395. doi: 10.1093/jnci/djae293.
Abstract
摘要
相似文献
1
Testing stored control-arm specimens could dramatically increase statistical power yet reduce costs in cancer screening trials.检测储存的对照臂样本可显著提高统计效能，同时降低癌症筛查试验的成本。
J Natl Cancer Inst. 2025 Mar 1;117(3):393-395. doi: 10.1093/jnci/djae293.
2
Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.通过检测对照臂样本提高筛查试验效能：在多癌检测筛查中的应用
J Natl Cancer Inst. 2024 Aug 1;116(8):1280-1287. doi: 10.1093/jnci/djae083.
3
Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.通过检测对照臂样本增加筛查试验的效能：多癌种检测筛查的应用。
J Natl Cancer Inst. 2024 Oct 1;116(10):1675-1682. doi: 10.1093/jnci/djae218.
4
Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.在普通人群中进行 SARS-CoV-2 监测的四种不同策略的有效性和成本效益（CoV-Surv 研究）：一项关于集群随机、双因素对照试验的研究方案的结构化总结。
Trials. 2021 Jan 8;22(1):39. doi: 10.1186/s13063-020-04982-z.
5
Retraction and Replacement of: Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
J Natl Cancer Inst. 2024 Oct 1;116(10):1706. doi: 10.1093/jnci/djae217.
6
Real-time adaptive randomization of clinical trials.临床试验的实时自适应随机化
J Clin Epidemiol. 2025 Feb;178:111612. doi: 10.1016/j.jclinepi.2024.111612. Epub 2024 Nov 16.
7
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区，服用抗叶酸抗疟药物的人群中，叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
8
More efficient, smaller multicancer screening trials.更高效、规模更小的多癌筛查试验。
J Natl Cancer Inst. 2025 Mar 1;117(3):450-455. doi: 10.1093/jnci/djae251.
9
Long-term prostate-specific antigen contamination in the Spanish arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC).欧洲前列腺癌筛查随机研究（ERSPC）西班牙分部的长期前列腺特异性抗原污染情况。
Actas Urol Esp. 2016 Apr;40(3):164-72. doi: 10.1016/j.acuro.2015.10.005. Epub 2015 Nov 24.
10
External control arm analysis: an evaluation of propensity score approaches, G-computation, and doubly debiased machine learning.外部控制臂分析：倾向评分方法、G-计算和双重无偏机器学习的评估。
BMC Med Res Methodol. 2022 Dec 28;22(1):335. doi: 10.1186/s12874-022-01799-z.
本文引用的文献
1
More efficient, smaller multicancer screening trials.更高效、规模更小的多癌筛查试验。
J Natl Cancer Inst. 2025 Mar 1;117(3):450-455. doi: 10.1093/jnci/djae251.
2
Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.通过检测对照臂样本增加筛查试验的效能：多癌种检测筛查的应用。
J Natl Cancer Inst. 2024 Oct 1;116(10):1675-1682. doi: 10.1093/jnci/djae218.
3
Effect of an Invitation or the Effect of Participation: What Should Randomized Controlled Trials of Cancer Screening Examine?邀请的效果还是参与的效果：癌症筛查随机对照试验应考察什么？
J Clin Oncol. 2024 Oct;42(28):3266-3269. doi: 10.1200/JCO.23.01673. Epub 2024 Jun 28.
4
Cancer Stage Compared With Mortality as End Points in Randomized Clinical Trials of Cancer Screening: A Systematic Review and Meta-Analysis.癌症分期与死亡率作为癌症筛查随机临床试验的终点：系统评价和荟萃分析。
JAMA. 2024 Jun 11;331(22):1910-1917. doi: 10.1001/jama.2024.5814.
5
Cancer screening with multicancer detection tests: A translational science review.多癌种检测试验进行癌症筛查：转化科学述评。
CA Cancer J Clin. 2024 Jul-Aug;74(4):368-382. doi: 10.3322/caac.21833. Epub 2024 Mar 22.
6
Randomized trials of multicancer screening tests: augmenting their ability to identify a genuine mortality benefit.随机多癌筛查试验：提高其识别真正死亡率获益的能力。
J Natl Cancer Inst. 2024 Jul 1;116(7):1005-1007. doi: 10.1093/jnci/djae059.
7
Study design considerations for trials to evaluate multicancer early detection assays for clinical utility.用于评估多癌种早期检测检测试剂盒临床实用性的临床试验设计考虑因素。
J Natl Cancer Inst. 2023 Mar 9;115(3):250-257. doi: 10.1093/jnci/djac218.
8
Cell-Free DNA-Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial.基于游离DNA的无症状筛查人群多癌早期检测试验（NHS-Galleri）：一项实用、前瞻性随机对照试验的设计
Cancers (Basel). 2022 Oct 1;14(19):4818. doi: 10.3390/cancers14194818.
9
An efficient randomised trial design for multi-cancer screening blood tests: nested enhanced mortality outcomes of screening trial.一种用于多癌筛查血液检测的高效随机试验设计：筛查试验的嵌套强化死亡率结果
Lancet Oncol. 2021 Oct;22(10):1360-1362. doi: 10.1016/S1470-2045(21)00204-7.
10
Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.英国卵巢癌筛查协作试验（UKCTOCS）长期随访后的卵巢癌人群筛查和死亡率：一项随机对照试验。
Lancet. 2021 Jun 5;397(10290):2182-2193. doi: 10.1016/S0140-6736(21)00731-5. Epub 2021 May 12.
Zotero 插件